{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T15:24:53Z","timestamp":1773242693477,"version":"3.50.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2007,10,22]],"date-time":"2007-10-22T00:00:00Z","timestamp":1193011200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2007,10,22]]},"DOI":"10.1007\/s10147-007-0695-5","type":"journal-article","created":{"date-parts":[[2007,10,10]],"date-time":"2007-10-10T08:33:24Z","timestamp":1192005204000},"page":"318-326","source":"Crossref","is-referenced-by-count":34,"title":["Proteasome inhibitor, bortezomib, for myeloma and lymphoma"],"prefix":"10.1007","volume":"12","author":[{"given":"Kensei","family":"Tobinai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,10,22]]},"reference":[{"key":"695_CR1","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1074-5521(01)00056-4","volume":"8","author":"AF Kisselev","year":"2001","journal-title":"Chem Biol"},{"key":"695_CR2","first-page":"2649","volume":"56","author":"CG Maki","year":"1996","journal-title":"Cancer Res"},{"key":"695_CR3","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1101\/gad.10.16.1979","volume":"10","author":"BE Clurman","year":"1996","journal-title":"Genes Dev"},{"key":"695_CR4","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0960-9822(00)00773-9","volume":"10","author":"H Tatebe","year":"2000","journal-title":"Curr Biol"},{"key":"695_CR5","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1038\/sj.onc.1202189","volume":"17","author":"C Cayrol","year":"1998","journal-title":"Oncogene"},{"key":"695_CR6","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1126\/science.7624798","volume":"269","author":"M Pagano","year":"1995","journal-title":"Science"},{"key":"695_CR7","first-page":"2615","volume":"59","author":"J Adams","year":"1999","journal-title":"Cancer Res"},{"key":"695_CR8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1006321828515","volume":"18","author":"J Adams","year":"2000","journal-title":"Invest New Drugs"},{"key":"695_CR9","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1038\/sj.onc.1204623","volume":"20","author":"T Hideshima","year":"2001","journal-title":"Oncogene"},{"key":"695_CR10","first-page":"3071","volume":"61","author":"T Hideshima","year":"2001","journal-title":"Cancer Res"},{"key":"695_CR11","doi-asserted-by":"crossref","first-page":"14\u2009374","DOI":"10.1073\/pnas.202445099","volume":"99","author":"N Mitsiades","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"695_CR12","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2002-08-2543","volume":"101","author":"T Hideshima","year":"2003","journal-title":"Blood"},{"key":"695_CR13","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0025-6196(12)61100-8","volume":"69","author":"MM Oken","year":"1994","journal-title":"Mayo Clin Proc"},{"key":"695_CR14","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/107327489800500302","volume":"5","author":"MM Oken","year":"1998","journal-title":"Cancer Control"},{"key":"695_CR15","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","volume":"16","author":"Myeloma Trialists Collaborative Group","year":"1998","journal-title":"J Clin Oncol"},{"key":"695_CR16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1532\/IJH97.03115","volume":"79","author":"T Takenaka","year":"2004","journal-title":"Int J Hematol"},{"key":"695_CR17","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198405243102104","volume":"310","author":"B Barlogie","year":"1984","journal-title":"N Engl J Med"},{"key":"695_CR18","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","volume":"349","author":"M Attal","year":"2003","journal-title":"N Engl J Med"},{"key":"695_CR19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"695_CR20","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","journal-title":"N Engl J Med"},{"key":"695_CR21","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","volume":"24","author":"B Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"key":"695_CR22","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1200\/JCO.1988.6.5.889","volume":"6","author":"AC Buzaid","year":"1988","journal-title":"J Clin Oncol"},{"key":"695_CR23","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/1097-0142(19910901)68:5<975::AID-CNCR2820680511>3.0.CO;2-O","volume":"68","author":"A Paccagnella","year":"1991","journal-title":"Cancer"},{"key":"695_CR24","doi-asserted-by":"crossref","unstructured":"Stewart KA, O'Connor OA, Alsina M, et al. (2007) Phase I evaluation of carfilzomib (PR-171) in hematological malignancies: responses in multiple myeloma and Waldenstrom's macroglobulinemia at well-tolerated doses. Proc Am Soc Clin Oncol 25: no. 8003","DOI":"10.1200\/jco.2007.25.18_suppl.8003"},{"key":"695_CR25","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","volume":"20","author":"RZ Orlowski","year":"2002","journal-title":"J Clin Oncol"},{"key":"695_CR26","first-page":"2505","volume":"8","author":"C Aghajanian","year":"2002","journal-title":"Clin Cancer Res"},{"key":"695_CR27","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"695_CR28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","volume":"127","author":"S Jagannath","year":"2004","journal-title":"Br J Haematol"},{"key":"695_CR29","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blade","year":"1998","journal-title":"Br J Haematol"},{"key":"695_CR30","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1182\/blood-2005-02-0691","volume":"106","author":"PG Richardson","year":"2005","journal-title":"Blood"},{"key":"695_CR31","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cncr.20888","volume":"103","author":"S Jagannath","year":"2005","journal-title":"Cancer"},{"key":"695_CR32","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1182\/blood-2005-03-1173","volume":"106","author":"S Lonial","year":"2005","journal-title":"Blood"},{"key":"695_CR33","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"P Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"695_CR34","doi-asserted-by":"crossref","unstructured":"Richardson PG, Sonneveld P, Schuster M, et al. (2005) Bortezomib continues demonstrate superior efficacy compared with high-dose dexamethasone in relapsed multiple myeloma: updated results of the APEX trial. Blood (ASH Annual Meeting Abstracts) 106: no. 2547","DOI":"10.1182\/blood.V106.11.2547.2547"},{"key":"695_CR35","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1158\/1078-0432.CCR-06-0170","volume":"12","author":"RC Kane","year":"2006","journal-title":"Clin Cancer Res"},{"key":"695_CR36","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2141.2007.06585.x","volume":"137","author":"PG Richardson","year":"2007","journal-title":"Br J Haematol"},{"key":"695_CR37","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"695_CR38","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2141.2005.05540.x","volume":"129","author":"S Jagannath","year":"2005","journal-title":"Br J Haematol"},{"key":"695_CR39","doi-asserted-by":"crossref","unstructured":"Harousseau JL, Nagler A, Sonneveld P, et al. (2007) Effect of the combination of pegylated liposomal doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed\/refractory multiple myeloma compared with bortezomib alone. Proc Am Soc Clin Oncol 25: no. 8002","DOI":"10.1200\/jco.2007.25.18_suppl.8002"},{"key":"695_CR40","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2004-07-2911","volume":"105","author":"RZ Orlowski","year":"2005","journal-title":"Blood"},{"key":"695_CR41","doi-asserted-by":"crossref","unstructured":"Tobinai K, Watanabe T, Ogawa Y, et al. (2006) Pharmacokinetic (PK) and pharmacodynamic (PD) profiles of bortezomib (B) in patients (pts) with relapsed multiple myeloma (MM): a phase I\/II study in Japan. Blood (ASH Annual Meeting Abstracts) 108: no. 5106","DOI":"10.1182\/blood.V108.11.5106.5106"},{"key":"695_CR42","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1182\/blood-2005-11-4541","volume":"107","author":"S Miyakoshi","year":"2006","journal-title":"Blood"},{"key":"695_CR43","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1532\/IJH97.06142","volume":"84","author":"A Gotoh","year":"2006","journal-title":"Int J Hematol"},{"key":"695_CR44","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","volume":"23","author":"A Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"695_CR45","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","volume":"23","author":"OA O'Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"695_CR46","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2005.04.6789","volume":"24","author":"SJ Strauss","year":"2006","journal-title":"J Clin Oncol"},{"key":"695_CR47","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/annonc\/mdl316","volume":"18","author":"A Belch","year":"2007","journal-title":"Ann Oncol"},{"key":"695_CR48","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"695_CR49","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"695_CR50","doi-asserted-by":"crossref","unstructured":"de Vos S, Dakhil S, McLaughlin P, et al. (2005) Bortezomib plus rituximab in patients with indolent non-Hodgkin's lymphoma (NHL): a phase 2 study. Blood (ASH Annual Meeting Abstracts) 106: no. 17","DOI":"10.1182\/blood.V106.11.17.17"},{"key":"695_CR51","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"695_CR52","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","volume":"23","author":"P Feugier","year":"2005","journal-title":"J Clin Oncol"},{"key":"695_CR53","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","volume":"24","author":"TM Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"695_CR54","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"695_CR55","doi-asserted-by":"crossref","unstructured":"Leonard JP, Furman RR, Cheung YK, et al. (2007) CHOP-R + bortezomib as initial therapy for diffuse large B-cell lymphoma (DLBCL). Proc Am Soc Clin Oncol 25: no. 8031","DOI":"10.1200\/jco.2007.25.18_suppl.8031"},{"key":"695_CR56","doi-asserted-by":"crossref","unstructured":"Mounier N, Ribrag V, Haioun C, et al. (2007) Efficacy and toxicity of two schedules of R-CHOP plus bortezomib in front-line B lymphoma patients: a randomized phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Proc Am Soc Clin Oncol 25: no. 8010","DOI":"10.1200\/jco.2007.25.18_suppl.8010"},{"key":"695_CR57","doi-asserted-by":"crossref","unstructured":"Zinzani PL, Tani M, Musuraca G, et al. (2006) Phase II study of proteasome inhibitor bortezomib (Velcade\u00ae) in patients with relapsed\/refractory T-cell lymphoma: preliminary results. Blood (ASH Annual Meeting Abstracts) 108: no. 2462","DOI":"10.1182\/blood.V108.11.2462.2462"},{"key":"695_CR58","first-page":"1083","volume":"62","author":"C Tan","year":"2002","journal-title":"Cancer Res"},{"key":"695_CR59","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/sj.leu.2403400","volume":"18","author":"Y Satou","year":"2004","journal-title":"Leukemia"},{"key":"695_CR60","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.2005.11.030","volume":"23","author":"VS Rajkumar","year":"2005","journal-title":"J Clin Oncol"},{"key":"695_CR61","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1200\/JCO.2005.03.2383","volume":"24","author":"JR Berenson","year":"2006","journal-title":"J Clin Oncol"},{"key":"695_CR62","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2141.2007.06656.x","volume":"138","author":"M Kropff","year":"2007","journal-title":"Br J Haematol"},{"key":"695_CR63","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3816\/CLM.2006.n.050","volume":"7","author":"A Suvannasankha","year":"2006","journal-title":"Clin Lymphoma Myeloma"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-007-0695-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-007-0695-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-007-0695-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,14]],"date-time":"2023-05-14T11:06:52Z","timestamp":1684062412000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-007-0695-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,22]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,10,22]]}},"alternative-id":["695"],"URL":"https:\/\/doi.org\/10.1007\/s10147-007-0695-5","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,22]]}}}